Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.

Background: Guselkumab is an interleukin (IL)-23 inhibitor with demonstrated efficacy in patients with psoriasis.

Objectives: Evaluate the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis. Correlate clinical response and disease duration data with serum biomarker data.

Bioprinting-Associated Shear Stress and Hydrostatic Pressure Affect the Angiogenic Potential of Human Umbilical Vein Endothelial Cells.

Bioprinting-associated shear stress and hydrostatic pressure can negatively affect the functionality of dispensed cells. We hypothesized that these mechanical stimuli can potentially affect the angiogenic potential of human umbilical vein endothelial cells (HUVECs). A numerical simulation model was used to calculate the shear stress during microvalve-based droplet ejection.

FRESH bioprinting technology for tissue engineering - the influence of printing process and bioink composition on cell behavior and vascularization.

The rapid and tailored biofabrication of natural materials is of high interest for the field of tissue engineering and regenerative medicine. Scaffolds require both high biocompatibility and tissue-dependent mechanical strength to function as basis for tissue-engineered implants. Thus, natural hydrogels such as fibrin are promising but their rapid biofabrication remains challenging.

Extracellular Vesicles-Loaded Fibrin Gel Supports Rapid Neovascularization for Dental Pulp Regeneration.

Rapid vascularization is required for the regeneration of dental pulp due to the spatially restricted tooth environment. Extracellular vesicles (EVs) released from mesenchymal stromal cells show potent proangiogenic effects. Since EVs suffer from rapid clearance and low accumulation in target tissues, an injectable delivery system capable of maintaining a therapeutic dose of EVs over a longer period would be desirable.